Pulmonology

Experts unpack new T2-targeted biologics for severe asthma and eosinophilic COPD, sharing biomarker tips, sequencing debates and payer hurdles,

Sanofi’s dual TSLP/IL‑13 bispecific cuts asthma exacerbations and shrinks nasal polyps, while atopic dermatitis results disappoint.

The Q1 recap for pulmonology spotlights regulatory and clinical advances across asthma and pulmonary fibrosis.

March 2026 saw new data from pivotal clinical trials and new expert conversations on HCPLive.

Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.

FDA approvals broaden ALYFTREK and TRIKAFTA eligibility to nearly 95% of US cystic fibrosis patients using a functional, mechanism-based variant criterion.

Deep learning applied to routine ECGs identifies subtle cardiac signals linked to early COPD, potentially enabling earlier diagnosis and intervention.

Deep learning applied to routine ECGs identified COPD up to 15 months earlier, supporting earlier intervention and risk stratification strategies.

AstraZeneca's investigational IL-33–targeting antibody tozorakimab met its primary endpoint in both the phase III OBERON and TITANIA trials.

Population study links respiratory allergies to hoarseness, throat clearing, and vocal fatigue, with greater symptom burden in women and unified airway implications.

Phase 3b ENCORE shows inhaled ARIKAYCE boosts culture conversion and symptoms in antibiotic‑naïve MAC lung disease, paving way for 2026 label expansion.

Clinicians compare newest asthma/COPD biologics, highlighting dupilumab’s edge, biomarker shifts, and insurance barriers shaping real-world use.

At AAAAI 2026, Ramsey discussed the shift toward race-neutral spirometry equations, their clinical implications, and barriers to widespread adoption.

Experts weigh new biologics including dupilumab, tezepelumab, and depemokimab, and how eosinophils guide real-world prescribing.

February 2026 saw new data and expert interviews from AAAAI 2026.

Using race-neutral spirometry equations such as GLI 2012 and GLI 2022 may improve diagnostic accuracy and reduce disparities in lung disease assessment.

Nguyen discussed how her study findings can help alleviate inhaled corticosteroid hesitancy for families.

Nguyen emphasized the safety of inhaled corticosteroids vs SABA-only therapy in pediatric asthma.

A new study stratified patients by longitudinal BEC patterns to assess whether variability in eosinophil levels influences response.

Retrospective analysis presented at AAAAI 2026 found 12%–15% risk reductions in asthma exacerbations over 3 years among patients without diabetes with overweight and obesity.

Bhatt discusses a recent study from GSK highlighting AREXVY’s efficacy in lowering major adverse cardiovascular events.

Claims study suggests dry powder and soft mist COPD inhalers cut exacerbations versus MDIs, offering greener care without added safety risks.

Seralutinib did improve 6-minute walk times and biomarkers, especially in patients with higher-risk disease.

A clinical forum focuses on how advanced practice providers (APP) and clinicians are now navigating how to translate emerging data into real-world practice.

These retrospective cohort studies also showed the vaccine’s reduction of heart attack, stroke, and asthma/COPD flare-ups in patients with RSV.